

## REMARKS

In response to the restriction requirement, Applicants elect Examiner's Group 3 (Claims 1-in-part, 2-4, 6-11 drawn to a method of assessing whether a subject who presents with an EGFR-expressing solid tumor, which does not express erbB2, is likely to exhibit a favorable clinical response to treatment comprising determining the pre-treatment level of pERK in said tumor).

Respectfully submitted,

Dated: 25 June 2007

/Virginia G. Campen/  
Virginia G. Campen  
Attorney for Applicant  
Reg. No. 37,092  
Tel. (919) 483-1012  
Fax. (919) 483-7988